Get started
Author

Melissa Timmons

Observed name: M. Timmons
OpenAlex ID: A5023203245
Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma
2022 · Yago Nieto, Pinaki P Banerjee, et al. · Blood · 24
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma
2018 · Yago Nieto, Peter F. Thall, et al. · Transplantation and Cellular Therapy · 17
PDF
Abstract 75: A phase I trial of mesenchymal stem cells transfected with a plasmid secreting interferon beta in advanced ovarian cancer
2018 · Michael Andreeff, Frank C. Marini, et al. · Cancer Research · 15
A Phase I Trial of Mesenchymal Stem Cells Transfected with a Plasmid Secreting Interferon Beta in Advanced Ovarian Cancer
2018 · Amanda Olson, Frank Marini, et al. · Transplantation and Cellular Therapy · 7
Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation
2019 · Amanda L. Olson, Ruitao Lin, et al. · Blood · 5
Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT).
2017 · Yago Nieto, Shi-Ming Tu, et al. · Journal of Clinical Oncology · 5
A clinical trial of intravenous mesenchymal stem cells for treatment of anthracycline associated cardiomyopathy
2019 · A. Olson, V. Al Jahdami, et al. · Cytotherapy · 3
A phase I trial of mesenchymal stem cells transfected with a plasmid secreting interferon beta in advanced ovarian cancer
2018 · A. Olson, F. Marini, et al. · Cytotherapy · 3
High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC)
2020 · Neeraj Saini, Junsheng Ma, et al. · Blood · 1
Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience
2020 · Yago Nieto, Stephen K. Gruschkus, et al. · Blood
Lymphomas: Hodgkin Lymphoma
2019 · Melissa Timmons · Springer Publishing Company eBooks
Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas
2017 · Yago Nieto, Peter F. Thall, et al. · Blood
Works count: 12
Citation count: 80
H-index: 5
I10-index: 3
Year
Topic
Type